Spyre Therapeutics to Participate in Upcoming Investor Conferences
Spyre Therapeutics (SYRE) Stock Trades At A Premium To Book Value
Spyre Therapeutics Announces Grants of Inducement Awards
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120
Spyre Therapeutics: Q3 Earnings Snapshot
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Spyre Therapeutics stock falls on public offering launch
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.